WHAT IS HERD IMMUNITY?

Herd immunity is reached when a sufficiently large proportion of a population has become immune to infection, not only protecting themselves, but also decreasing the likelihood of transmission of disease to remaining susceptible persons. Immune persons thus form a barrier to slow or prevent the disease outbreak among other members of the “herd.”

The critical proportion of a population ($p_c$) needed to be immune to a disease before herd immunity becomes protective is roughly estimated using the basic reproductive number ($R_0$) of the disease as follows:

$$p_c = 1 - \frac{1}{R_0}$$

$R_0$ is an average that varies by factors such as population density, age structure, individual behaviors, and social interactions. For coronavirus disease 2019 (COVID-19), $R_0$ varies globally, but typically is about 3.0 [1], which means that we would need roughly 67% of the population to be immune. In the absence of a vaccine or pre-existing immunity, this means allowing two-thirds of the population to be infected, which can come with dire consequences.

In this paper, we describe why a strategy that aims to reach herd immunity against COVID-19 in the absence of a vaccine is deeply irresponsible.

KEY WORDS: Herd immunity, Vaccines, Coronavirus, Ethics, Endemic diseases

COVID-19 herd immunity in the absence of a vaccine: an irresponsible approach

Jade Khalife¹, Derrick VanGennep²

¹Social Medicine and Global Health, Faculty of Medicine, Lund University, Malmö, Sweden; ²New England Complex Systems Institute, Cambridge, MA, USA.

As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread rapidly throughout the human population, the concept of “herd immunity” has attracted the attention of both decision-makers and the general public. In the absence of a vaccine, this entails that a large proportion of the population will be infected to develop immunity that would limit the severity and/or extent of subsequent outbreaks. We argue that adopting such an approach should be avoided for several reasons. There are significant uncertainties about whether achieving herd immunity is possible. If possible, achieving herd immunity would impose a large burden on society. There are gaps in protection, making it difficult to shield the vulnerable. It would defeat the purpose of avoiding harm caused by the virus. Lastly, dozens of countries are showing that containment is possible.

KEY WORDS: Herd immunity, Vaccines, Coronavirus, Ethics, Endemic diseases

WHAT IS HERD IMMUNITY?

Herd immunity is reached when a sufficiently large proportion of a population has become immune to infection, not only protecting themselves, but also decreasing the likelihood of transmission of disease to remaining susceptible persons. Immune persons thus form a barrier to slow or prevent the disease outbreak among other members of the “herd.”

The critical proportion of a population ($p_c$) needed to be immune to a disease before herd immunity becomes protective is roughly estimated using the basic reproductive number ($R_0$) of the disease as follows:

$$p_c = 1 - \frac{1}{R_0}$$

$R_0$ is an average that varies by factors such as population density, age structure, individual behaviors, and social interactions. For coronavirus disease 2019 (COVID-19), $R_0$ varies globally, but typically is about 3.0 [1], which means that we would need roughly 67% of the population to be immune. In the absence of a vaccine or pre-existing immunity, this means allowing two-thirds of the population to be infected, which can come with dire consequences.

In this paper, we describe why a strategy that aims to reach herd immunity against COVID-19 in the absence of a vaccine is deeply irresponsible.

It results in a large loss of life, more severe disease, and long-term harm

The COVID-19 infection fatality ratio (IFR) varies by population age, comorbidities, healthcare access, and other factors, but can be expected to range between 0.37% and 1.45% [2]. This would make COVID-19 at least 10 times worse than seasonal influenza, meaning that reaching 67% infection would roughly translate into about 24,790 to 97,150 deaths in a population of 10 million people—for their first infection only. This provides an idea of the scale of deaths involved. However, in the real world, the spread of the disease would not instantly stop once 67% of persons are infected; instead, disease spread would continue further and over-shoot to some extent. More lives would be lost if the healthcare system is overwhelmed by having to care for over a million persons who would present with severe or critical disease due to COVID-19 [3].
Another consequence of such an approach would be accepting that many, if not most, survivors would develop persistent symptoms and chronic conditions. Evidence is already accumulating of chronic damage to the lungs, brain, heart, kidneys, and other organs and body systems due to COVID-19 [4-8]. This largely neglected burden remains uncaptured in national and international tallies. The patient-created term “long COVID” has been used for long-term sequelae caused by the disease, such as fever, fatigue, headache, loss of smell/taste, myalgia, and shortness of breath. Up to 1 in 5 of COVID-positive persons reported such symptoms for 5 weeks or longer, while 1 in 10 reported them for 12 weeks or longer, with a median of 40 days [9]. Even among those with mild or initially asymptomatic infections, 21% reported symptoms for 30 days or longer after infection [10]. COVID-19 is more accurately considered to be a complex and multi-system disorder, rather than a respiratory disease [11], with a long-term impact certain to contribute to the global burden of various diseases.

It results in endemic disease, not the absence of disease, with ongoing harm

Herd immunity, if at all reachable, is not a one-time achievement, but has to be maintained through new infections (and consequently deaths). This is largely due to 2 aspects: population flux and duration of functional immunity. With populations constantly in flux due to births, deaths, and migration, new infections must continually occur to maintain the protective threshold. The immunity duration for COVID-19 is uncertain, possibly ranging from a few months to a few years. For severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1, in the 2002-2004 outbreak) immunity typically lasted 2 years [12], and for seasonal coronaviruses only 6-12 months [13]. We know that COVID-19 reinfection is possible, following the confirmation of a few persons who were infected a second time a few months after their initial infection [14,15]. However, until wider investigations are conducted, the extent and duration of immunity remains uncertain.

Maintaining herd immunity with new infections would also have to occur at a rate that avoids overwhelming the healthcare system, otherwise death rates could increase considerably. This also means that some physical distancing measures would likely become permanent, together with the associated costs to society.

Herd immunity would also be a misleading term in the absence of a vaccine. It suggests that a community has become immune, whereas in reality the disease would have become endemic and many people would still continue to be infected.

Protecting large vulnerable groups becomes nearly impossible, as they cannot safely participate in society where disease is endemic

Herd immunity functions at the level of the population and of surrounding contacts. If more than two-thirds of a population is immune to COVID-19 (due to previous infection), this may be protective for the remaining non-immune persons. However, no population is completely homogeneous. Persons with contacts who are largely not immune would form unprotected pockets vulnerable to outbreaks. This particularly applies to elderly individuals in nursing homes, as well as remote/rural/religious/other communities that are to some extent less inter-mixed with the population majority or have been less exposed to the disease.

Reinfection undermines immunity, especially because the disease can be more severe in subsequent infections

In general, persons reinfected with COVID-19 would be expected to have a less severe course than their previous infection, due to the presence of long-term memory cells. However, exceptions exist where viral reinfection triggers a reaction worse than the initial infection, as in dengue fever [16]. This also seems to be the case in 8 of the 24 COVID-19 reinfections confirmed to date [17]. It is also relevant to consider that some COVID-19 survivors may have more severe or fatal reinfections due to chronic damage sustained from their previous infection. This further contributes to the list of uncertainties.

It is relevant to distinguish between functional immunity, which protects from illness, and the body’s immune response. Recent research has found that antibody levels for COVID-19, made by B lymphocyte cells, steeply decline only 2-3 months following infection [18,19]. This pattern is typical of the immune response to viral threats. The harder-to-detect T lymphocyte cells (e.g. helper, cytotoxic, memory T-cells) typically have a greater role in longer-term immunity than antibody levels, as do B lymphocytes themselves. A preliminary study found that while some T-cells decreased within a few months of infection, B-cells remained stable up to 6 months after infection [20]. However, we currently lack sufficient knowledge on how this translates to functional immunity to COVID-19.

It is also unknown whether the recently discovered cross-reactivity of T-cells from other coronaviruses (e.g., previous common cold infection) would confer any advantage to persons infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, which causes COVID-19) [21-23]. If it does, this would be in the form of reduced severity or speed of severity progression, but it would not impact infection, as T-cells are activated after viral replication within cells has already occurred (i.e., after infection). It is also uncertain whether such cross-reactivity may actually worsen the outcome of severe COVID-19 in some individuals [24].

Containing the virus has been successful in dozens of countries, while attempting herd immunity has failed with a high cost

Approximately 30 countries are succeeding at containment of COVID-19, with zero or near-zero daily cases [25]. These include large populations in low/middle-income countries such as Cambodia, Laos, Mongolia, Thailand, and Vietnam, as well as Australia, China, New Zealand, Singapore, and Taiwan.

Some countries initially chose to aim towards herd immunity, either implicitly or explicitly, such as the United States, United...
Suppressing the disease gives time for the development of treatments and vaccines

The time gained by suppressing transmission is valuable, as it allows the development of more effective medications and treatment approaches for COVID-19 cases. Survival outcomes of COVID-19 have already improved since the early months of the outbreak due to such developments, including the use of anticoagulant therapy and systemic corticosteroids for severe or critical cases. Other trials are also underway, such as those for monoclonal antibodies. As such, arguments that a herd immunity approach simply involves up-fronting the costs (or deaths) are misleading.

It defeats the purpose of reducing harm caused by the virus

Aiming at herd immunity in the absence of a vaccine for a disease with a relatively high mortality rate such as COVID-19 defeats the purpose of this public health approach, namely, to save lives. A strategy that allows people to be infected by a disease is not one that protects them from the disease. While preventing healthcare systems from being overwhelmed is important, it is the system that serves the individual, not the other way around.

Protecting the most vulnerable members of society is a defining feature of humanity. Allowing their exposure to the great harm posed by such a herd immunity approach makes this not only an unscientific gamble, but also highly unethical.

There are various uncertainties associated with a novel virus

An approach aiming at herd immunity without using a vaccine involves several uncertainties, including uncertainty regarding the extent and duration of immunity, severity of reinfection, role of cross-reactivity, persistent symptoms, and chronic conditions. Another aspect to consider is that every infected person is a laboratory for potential new viral strains to emerge through mutation and recombination. Recently, a new strain (lineage B.1.1.7) was first identified in the United Kingdom, with preliminary reports suggesting it could be up to 70% more transmissible than previous strains. Allowing large numbers of people to be continually infected means keeping a wider door open for new viral strains.

Animals also pose a significant risk. Recently, more than 200 human cases of COVID-19 have been identified in Denmark with SARS-CoV-2 variants associated with farmed minks, including 12 cases with a unique variant [30]. Denmark, the Netherlands, Spain, Sweden, Italy, and the United States have all reported SARS-CoV-2 in farmed minks [30]. It is possible that the virus could also cross to other similar animals such as mice, voles, rats, and ferrets, providing more opportunities for it to evolve and cross back to humans. Providing more such opportunities for the virus among both humans and animals would therefore be unwise.

Towards the end of 2020 there has been much news coming from a few clinical trials of vaccine candidates. However, in most countries, vaccination is unlikely to reach the majority of the public until mid- to late 2021. Importantly, these vaccines could be a powerful tool to help eliminate the virus, but the timeline is too lengthy to justify only waiting for vaccination. Even under optimal conditions, vaccine efficacy will not be 100%; not all persons vaccinated will be protected. In a real-world environment, further
Epidemiol Health 2021;43:e2021012

Barriers to effectiveness will also be encountered, including availability and uptake by populations. In many countries, it may be years before herd immunity through vaccination is reached. Furthermore, since immunity duration is still uncertain, the possibility remains that protection may be short-lived, thereby limiting the effectiveness of vaccination. Improved mechanisms for surveillance, monitoring, response, and treatment will remain necessary beyond vaccination.

CONCLUSION

The greatest benefit for populations in both health and economic terms lies in containing and pursuing elimination of COVID-19. Over 30 countries are showing us how. Vaccination will further protect populations from its re-emergence. However, pursuing herd immunity without a vaccine involves numerous uncertainties, is costly in terms of lives and disease, is ineffective, and—being unethical and uncompassionate—is not compatible with human dignity and development.

Ethics statement

Not applicable as the manuscript did not involve any experimentation.

CONFLICT OF INTEREST

The authors have no conflicts of interest to declare for this study.

FUNDING

None.

ACKNOWLEDGEMENTS

None.

AUTHOR CONTRIBUTIONS

Conceptualization: JK, DV. Funding acquisition: None. Writing – original draft: JK, DV. Writing – review & editing: JK, DV.

ORCID

Jade Khalife: https://orcid.org/0000-0001-8765-0142; Derrick VanGennep: https://orcid.org/0000-0002-8944-3486

REFERENCES

1. Alimohamadi Y, Taghdr M, Sepandi M. Estimate of the basic reproduction number for COVID-19: a systematic review and meta-analysis. J Prev Med Public Health 2020;53:151-157.
2. Ghisolfi S, Almås I, Sandefur JC, von Carnap T, Heitner J, Bold T. Predicted COVID-19 fatality rates based on age, sex, comorbidities and health system capacity. BMJ Glob Health 2020;5:e003094.
3. World Health Organization. Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19); 2020 Feb 28 [cited 2020 Nov 21]. Available from: https://www.who.int/publications/i/item/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19).
4. Carfi A, Bernabei R, Landi F; Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA 2020;324:603-605.
5. Zubair AS, McAlpine LS, Gardin T, Farhadian S, Kuruvilla DE, Spudich S. Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: a review. JAMA Neurol 2020;77:1018-1027.
6. Stewart DJ, Hartley JC, Johnson M, Marks SD, du Pré P, Stojanovic J. Renal dysfunction in hospitalised children with COVID-19. Lancet Child Adolesc Health 2020;4:e28-e29.
7. Mitramani RD, Dabas N, Goldberger JJ. COVID-19 cardiac injury: implications for long-term surveillance and outcomes in survivors. Heart Rhythm 2020;17:1984-1990.
8. Romero-Sánchez CM, Díaz-Maroto I, Fernández-Díaz E, Sánchez-Larsen A, Layos-Romero A, García-García J, et al. Neurologic manifestations in hospitalized patients with COVID-19: the ALBACOVID registry. Neurology 2020;95:e1060-e1070.
9. Office for National Statistics. The prevalence of long COVID symptoms and COVID-19 complications; 2020 Dec 16 [cited 2021 Jan 28]. Available from: https://www.ons.gov.uk/news/statementsandletters/theprevalenceoflongcovidssymptomsandcovid19complications.
10. Cirulli E, Barrett KM, Riffle S, Bolze A, Neveux I, Dabe S, et al. Long-term COVID-19 symptoms in a large unselected population. medRxiv 2020. doi: https://doi.org/10.1101/2020.10.07.20208702.
11. Roberts CM, Levi M, McKee M, Schilling R, Lim WS, Grocott MP. COVID-19: a complex multisystem disorder. Br J Anaesth 2020;125:238-242.
12. Wu LP, Wang NC, Chang YH, Tian XY, Na DY, Zhang LY, et al. Duration of antibody responses after severe acute respiratory syndrome. Emerg Infect Dis 2007;13:1562-1564.
13. Edridge AW, Kaczorowska J, Hoste AC, Bakker M, Klein M, Loens K, et al. Seasonal coronavirus protective immunity is short-lasting. Nat Med 2020;26:1691-1693.
14. To KK, Hung IF, Ip JD, Chu AW, Chan WM, Tam AR, et al. COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. Clin Infect Dis 2020;ciaa1275.
15. NOS. Also reinfections in the Netherlands and Belgium [cited 2020 Aug 29]. Available from: https://nos.nl/artikel/2345309-oook-herbesmettingen-in-nederland-en-belgie.html (Dutch).
16. Katzelnick LC, Gresh L, Halloran ME, Mercado JC, Kuan G, Gordon A, et al. Antibody-dependent enhancement of severe dengue disease in humans. Science 2017;358:929-932.
17. BNO News. COVID-19 reinfection tracker; 2020 Aug 28 [cited...
20. Dan JM, Mateus J, Kato Y, Hastie KM, Faliti C, Ramirez SI, et al. Immunological memory to SARS-CoV-2 assessed for greater than six months after infection. bioRxiv 2020. doi: https://doi.org/10.1101/2020.11.15.383323.
21. Le Bert N, Tan AT, Kunasegaran K, Tham CY, Hafezi M, Chia A, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature 2020;584:457-462.
22. Mateus J, Grifoni A, Tarke A, Sidney J, Ramirez SI, Dan JM, et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science 2020;370:89-94.
23. Sekine T, Perez-Potti A, Rivera-Ballesteros O, Strålin K, Gorin JB, Olsson A, et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell 2020;183:158-168.
24. Thieme CJ, Anft M, Paniskaki K, Blazquez-Navarro A, Seibert FS, et al. Robust T cell response toward spike, membrane, and nucleocapsid SARS-CoV-2 proteins is not associated with recovery in critical COVID-19 patients. Cell Rep Med 2020;1:100092.
25. EndCoronavirus. Some are winning - some are not: which countries do best in beating COVID-19? [cited 2021 Jan 31]. Available from: https://www.endcoronavirus.org/countries.
26. Swedish Public Health Agency. Number of cases of covid-19 in Sweden - data up to and including the previous day are published weekdays [cited 2021 Jan 31]. Available from: https://experience.arcgis.com/experience/09f821667ce64fb7be6f9b7457ed9aa (Swedish).
27. Ritchie H, Ortiz-Ospina E, Beltekian D, Mathieu E, Hasell J, Macdonald B, et al. Coronavirus pandemic (COVID-19) [cited 2020 Jan 26]. Available from: https://ourworldindata.org/coronavirus.
28. Buss LF, Prete CA Jr, Abraham CM, Mendrone A Jr, Salomon T, de Almeida-Neto C, et al. Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic. Science 2021;371:288-292.
29. Sabino EC, Buss LF, Carvalho MP, Prete CA Jr, Crispim MA, Fraiji NA, et al. Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. Lancet 2021;397:452-455.
30. World Health Organization. SARS-CoV-2 mink-associated variant strain – Denmark; 2020 Nov 6 [cited 2020 Dec 3]. Available from: https://www.who.int/csr/don/06-november-2020-mink-associated-sars-cov2-denmark/en/.